3
|
Rocha N, Payne F, Huang-Doran I, Sleigh A, Fawcett K, Adams C, Stears A, Saudek V, O’Rahilly S, Barroso I, Semple RK. The metabolic syndrome- associated small G protein ARL15 plays a role in adipocyte differentiation and adiponectin secretion. Sci Rep 2017; 7:17593. [PMID: 29242557 PMCID: PMC5730586 DOI: 10.1038/s41598-017-17746-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2017] [Accepted: 11/30/2017] [Indexed: 02/02/2023] Open
Abstract
Common genetic variants at the ARL15 locus are associated with plasma adiponectin, insulin and HDL cholesterol concentrations, obesity, and coronary atherosclerosis. The ARL15 gene encodes a small GTP-binding protein whose function is currently unknown. In this study adipocyte-autonomous roles for ARL15 were investigated using conditional knockdown of Arl15 in murine 3T3-L1 (pre)adipocytes. Arl15 knockdown in differentiated adipocytes impaired adiponectin secretion but not adipsin secretion or insulin action, while in preadipocytes it impaired adipogenesis. In differentiated adipocytes GFP-tagged ARL15 localized predominantly to the Golgi with lower levels detected at the plasma membrane and intracellular vesicles, suggesting involvement in intracellular trafficking. Sequencing of ARL15 in 375 severely insulin resistant patients identified four rare heterozygous variants, including an early nonsense mutation in a proband with femorogluteal lipodystrophy and non classical congenital adrenal hyperplasia, and an essential splice site mutation in a proband with partial lipodystrophy and a history of childhood yolk sac tumour. No nonsense or essential splice site mutations were found in 2,479 controls, while five such variants were found in the ExAC database. These findings provide evidence that ARL15 plays a role in adipocyte differentiation and adiponectin secretion, and raise the possibility that human ARL15 haploinsufficiency predisposes to lipodystrophy.
Collapse
Affiliation(s)
- Nuno Rocha
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,grid.454369.9The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
| | - Felicity Payne
- 0000 0004 0606 5382grid.10306.34Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, UK
| | - Isabel Huang-Doran
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,grid.454369.9The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
| | - Alison Sleigh
- 0000000121885934grid.5335.0Wolfson Brain Imaging Centre, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK ,0000 0004 0383 8386grid.24029.3dNational Institute for Health Research/Wellcome Trust Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK
| | - Katherine Fawcett
- 0000 0004 0606 5382grid.10306.34Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, UK
| | - Claire Adams
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,grid.454369.9The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
| | - Anna Stears
- 0000 0004 0383 8386grid.24029.3dWolfson Diabetes and Endocrine Clinic, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - Vladimir Saudek
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,grid.454369.9The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
| | - Stephen O’Rahilly
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,grid.454369.9The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
| | - Inês Barroso
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,0000 0004 0606 5382grid.10306.34Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, UK
| | - Robert K. Semple
- 0000 0004 0369 9638grid.470900.aThe University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, UK ,grid.454369.9The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK ,0000 0004 1936 7988grid.4305.2Centre for Cardiovascular Sciences, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK
| |
Collapse
|
9
|
Nyabi O, Naessens M, Haigh K, Gembarska A, Goossens S, Maetens M, De Clercq S, Drogat B, Haenebalcke L, Bartunkova S, De Vos I, De Craene B, Karimi M, Berx G, Nagy A, Hilson P, Marine JC, Haigh JJ. Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. Nucleic Acids Res 2009; 37:e55. [PMID: 19279185 PMCID: PMC2673446 DOI: 10.1093/nar/gkp112] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2008] [Revised: 01/15/2009] [Accepted: 02/10/2009] [Indexed: 11/25/2022] Open
Abstract
The ability to rapidly and efficiently generate reliable Cre/loxP conditional transgenic mice would greatly complement global high-throughput gene targeting initiatives aimed at identifying gene function in the mouse. We report here the generation of Cre/loxP conditional ROSA26-targeted ES cells within 3-4 weeks by using Gateway cloning to build the target vectors. The cDNA of the gene of interest can be expressed either directly by the ROSA26 promoter providing a moderate level of expression or by a CAGG promoter placed in the ROSA26 locus providing higher transgene expression. Utilization of F1 hybrid ES cells with exceptional developmental potential allows the production of germ line transmitting, fully or highly ES cell-derived mice by aggregation of cells with diploid embryos. The presented streamlined procedures accelerate the examination of phenotypical consequences of transgene expression. It also provides a unique tool for comparing the biological activity of polymorphic or splice variants of a gene, or products of different genes functioning in the same or parallel pathways in an overlapping manner.
Collapse
Affiliation(s)
- Omar Nyabi
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Michael Naessens
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Katharina Haigh
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Agnieszka Gembarska
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Steven Goossens
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Marion Maetens
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Sarah De Clercq
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Benjamin Drogat
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Lieven Haenebalcke
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Sonia Bartunkova
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Ilse De Vos
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Bram De Craene
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Mansour Karimi
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Geert Berx
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Andras Nagy
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Pierre Hilson
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Jean-Christophe Marine
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| | - Jody J. Haigh
- Vascular Cell Biology Unit, Department for Molecular Biomedical Research, VIB, Department of Biomedical Molecular Biology, Ghent University, Laboratory for Molecular Cancer Biology, VIB-UGent, Molecular and Cellular Oncology Unit, Department for Molecular Biomedical Research, Department of Plant Systems Biology, VIB, Department of Molecular Genetics, Ghent University, Gent, Belgium, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada
| |
Collapse
|